These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 19920113)

  • 1. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
    Bruheim S; Xi Y; Ju J; Fodstad O
    Clin Cancer Res; 2009 Dec; 15(23):7161-9. PubMed ID: 19920113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
    Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
    Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles.
    Ochi K; Daigo Y; Katagiri T; Nagayama S; Tsunoda T; Myoui A; Naka N; Araki N; Kudawara I; Ieguchi M; Toyama Y; Toguchida J; Yoshikawa H; Nakamura Y
    Int J Oncol; 2004 Mar; 24(3):647-55. PubMed ID: 14767549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
    Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
    Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
    Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
    Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response.
    Fumoto S; Shimokuni T; Tanimoto K; Hiyama K; Otani K; Ohtaki M; Hihara J; Yoshida K; Hiyama E; Noguchi T; Nishiyama M
    Int J Oncol; 2008 Feb; 32(2):413-23. PubMed ID: 18202764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel genes involved in the synergistic antitumor effect of caffeine in osteosarcoma cells using cDNA macroarray.
    Ii S; Ueda Y; Shimazaki M; Katsuta S; Takazawa K; Kanazawa Y; Tomita K; Tsuchiya H
    Anticancer Res; 2008; 28(2A):645-53. PubMed ID: 18507003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo.
    Suto R; Abe Y; Nakamura M; Ohnishi Y; Yoshimura M; Lee YH; Imanishi T; Yamazaki H; Kijima H; Tokunaga T; Oshika Y; Hiraoka N; Tamaoki N; Fukuda H; Ueyama Y
    Int J Oncol; 1998 Feb; 12(2):287-91. PubMed ID: 9458350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
    Hingorani P; Zhang W; Piperdi S; Pressman L; Lin J; Gorlick R; Kolb EA
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.
    Orosco A; Fromigué O; Bazille C; Entz-Werle N; Levillain P; Marie PJ; Modrowski D
    Cancer Res; 2007 Apr; 67(8):3708-15. PubMed ID: 17440083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
    Fiebig HH; Schüler J; Bausch N; Hofmann M; Metz T; Korrat A
    Cancer Genomics Proteomics; 2007; 4(3):197-209. PubMed ID: 17878523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.
    Imanishi T; Abe Y; Suto R; Higaki S; Ueyama Y; Nakamura M; Tamaoki N; Fukuda H; Imai N
    Tokai J Exp Clin Med; 1994 Sep; 19(1-2):39-46. PubMed ID: 7660382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
    Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
    Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
    Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.